ANI Pharmaceuticals Gains FDA Approval, Launches Limited-Competition Isosorbide Mononitrate Generic
ANIP sits 40% above its 52-week low of $56.71.
Summary
ANI Pharmaceuticals announced it has received FDA approval for its Abbreviated New Drug Application (ANDA) for Isosorbide Mononitrate Tablet USP (10 mg and 20 mg), a generic version of Monoket®, and has immediately launched the product. This approval and launch introduce a new generic product to the market, which the company highlights as a 'limited-competition product.' This event is a positive catalyst, indicating a new revenue stream and reinforcing ANI's R&D capabilities and operational execution. Traders will be watching for initial sales performance and market share capture of this new generic offering.
At the time of this announcement, ANIP was trading at $79.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $56.71 to $99.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.